Search results
Results from the WOW.Com Content Network
Glecaprevir (INN, [1]) is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that was identified jointly by AbbVie and Enanta Pharmaceuticals. [2] It is being developed as a treatment of chronic hepatitis C infection in co-formulation with an HCV NS5A inhibitor pibrentasvir.
Sofosbuvir is also used with other medications and longer treatment durations, depending on specific circumstances, genotype and cost-effectiveness–based perspective. For example, for the treatment of genotypes 1, 4, 5, and 6 hepatitis C infections, sofosbuvir can be used in combination with the viral NS5A inhibitor ledipasvir. [16]
Treatment of people aged twelve years of age and older with solid tumors that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy [2]
In fact, the rate of new hepatitis C cases more than quadrupled over the last decade, according to a study conducted by the Centers for Disease Control and Prevention (CDC). Dr. Dr.
[5] [6] It works against all six types of hepatitis C. [4] At twelve weeks following treatment between 81% and 100% of people have no evidence of hepatitis C. [7] It is taken once a day by mouth with food. [4] [5] The most common side effects are headache, diarrhea, and tiredness. [7] [8] In those with a history of hepatitis B, reactivation may ...
Bristol-Myers Squibb's (NYS: BMY) latest data on its current hepatitis C drugs explain why the pharma needed to purchase Inihibitex (NAS: INHX) . A combination of its drugs -- daclatasvir and ...
Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. [2] [5] [6] [7] It combines sofosbuvir and velpatasvir. [2] [5] [6] It is more than 90% effective for hepatitis C genotypes one through six. [2]
Sofosbuvir is a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus. Gilead Sciences has received FDA priority review status for its New Drug Application ...